Here are relevant reports on : cancer-immunotherapy-market
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
US Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The US artificial intelligence (AI) in healthcare market, valued at US$5.98 billion in 2024, stood at US$8.65 billion in 2025 and is projected to advance at a resilient CAGR of 38.0% from 2025 to 2030, culminating in a forecasted valuation of US$43.30 billion by the end of the period. Market growth is driven by rising demand from providers for automation, nationwide labor shortages, increasing clinical complexity, and strong investment in predictive analytics, imaging AI, and GenAI.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals), Region - Global Forecast to 2030
The global Artificial Intelligence (AI) in healthcare market, valued at US$14.92B in 2024, is forecasted to grow at a 38.6% CAGR, reaching US$21.66B by 2025 and US$110.61B by 2030. Market growth in the Asia Pacific can be attributed to the presence of a large and growing patient population, a gradual shift toward adopting technologies such as automation, data analytics, and cloud computing, and increasing spending on HCIT infrastructure.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) & Region - Global Forecast to 2028
The global tissue diagnostics market, valued at US$5.2 billion in 2022, stood at US$5.6 billion in 2023 and is projected to advance at a resilient CAGR of 8.4% from 2023 to 2028, culminating in a forecasted valuation of US$8.4 billion by the end of the period. The new research study consists of an industry trend analysis of the market. Market growth is driven by the growing private diagnostic centers globally, and rising geriatric population with subsequent growth in chronic and infectious diseases.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Cytology Brush Market by Product Type (Disposable & Reusable), Disease Type (Lung Cancer, Ovarian cancer, & Others), and End User (Hospitals, Ambulatory Surgical Centers, & Others) - Global Forecast to 2023
The global cytology brush market is expected to reach USD 83.1million by 2023 from USD 64.5 million in 2018, growing at a CAGR of 5.2%. Increasing awareness and demand for minimally invasive procedures, increasing incidence of cancer, and rising awareness about early diagnosis especially for cancer and are some of the major factors driving the growth of the global cytology brush market.
- Published: March 2026
- Price: $ 8150
- TOC Available:
-
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), End-user, and Region - Global Forecast to 2029
The global cancer biomarkers market, valued at US$22.3 billion in 2023, stood at US$24.5 billion in 2024 and is projected to advance at a resilient CAGR of 11.3% from 2024 to 2029, culminating in a forecasted valuation of US$42.0 billion by the end of the period. The primary drivers of growth in this market are the rising incidence of cancer worldwide, increased research on cancer biomarkers, the growing use of biomarkers in drug discovery and development, and ongoing technical advancements.
- Published: April 2024
- Price: $ 7150
- TOC Available:
-
Cancer Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
The global cancer profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. The growth in this market is driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players. On the other hand, a low biomarker discovery-to-approval ratio and a poor regulatory and reimbursement scenario challenge the growth of the cancer profiling market.
- Published: November 2022
- Price: $ 4950
- TOC Available:
-
Endoscopic Submucosal Dissection/ESD Market by Product (Gastroscopes & Endoscopes, Injection Agent, Tissue Retractor), Indication (Stomach Cancer, Colon Cancer), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center) - Global Forecast to 2030
The global endoscopic submucosal dissection market, valued at US$0.46 billion in 2024, stood at US$0.50 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$0.75 billion by the end of the period. The increasing adoption of endoscopic submucosal dissection (ESD) in Western countries is becoming a significant growth driver for the global ESD market.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Forecast to 2024
The Cancer Registry Software Market is projected to reach USD 91 million by 2024, at a CAGR of 10.4%. Factors such as the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market. However, factors such as privacy and data security-related concerns are expected to restrain the growth of this market to a certain extent.Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US).
- Published: March 2019
- Price: $ 11000
- TOC Available:
-
Fiber Food Ingredients Market, By Type Soluble Fiber, Insoluble Fiber, Resistant Fibres, Others) By Function (Cancer
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
